In case you missed it, biotech analyst Brian Skorney and industry veteran Daphne Zohar joined “The Readout Loud,” STAT’s ...

GSK market cap is currently £55.9B and has a P/E ratio of 22.22. Based on the recent corporate insider activity of 333 insiders, corporate insider sentiment is positive on the stock. This means that ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory syncytial virus vaccine raked in just $10 ...

High tissue distribution into organs of concern for invasive fungal infections.

Shares of GSK PLC GSK dropped 1.59% to £13.92 Tuesday, on what proved to be an all-around poor trading session for the stock ...

GlaxoSmithKline (GSK) has released an update. GlaxoSmithKline (GSK) has announced that its issued share capital as of October 31, 2024, ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

AnaptysBio has a past history of successes. There are 2 molecules in phase 2, but with no patient data. GSK news has hurt ANAB stock. Read more here.

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

GSK stock crumbled on Wednesday after vaccine sales tumbled, leading to a third-quarter miss. Revenue from RSV shot Arexvy ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...